JAK Inhibitors in Rheumatoid Arthritis: An Evidence-Based Review on the Emerging Clinical Data
Robert Harrington,* Shamma Ahmad Al Nokhatha,* Richard Conway Department of Rheumatology, St. James’s Hospital, Dublin, Ireland*These authors contributed equally to this workCorrespondence: Richard ConwayDepartment of Rheumatology, St. James’s Hospital, Dublin, IrelandEmail drric...
Guardado en:
Autores principales: | Harrington R, Al Nokhatha SA, Conway R |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2020
|
Materias: | |
Acceso en línea: | https://doaj.org/article/fecb9d1c8873496db890a1eafdd3a753 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Preclinical Characterization of the Selective JAK1 Inhibitor LW402 for Treatment of Rheumatoid Arthritis
por: Zhang N, et al.
Publicado: (2021) -
An Update for the Clinician on Biologics for the Treatment of Psoriatic Arthritis
por: Chimenti MS, et al.
Publicado: (2020) -
Current and Emerging DMARDs for the Treatment of Rheumatoid Arthritis
por: Mysler E, et al.
Publicado: (2021) -
Management of Rheumatoid Arthritis: An Overview
por: Andrei-Flavius Radu, et al.
Publicado: (2021) -
Management of rheumatoid arthritis during pregnancy: challenges and solutions
por: Krause ML, et al.
Publicado: (2016)